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June Supplement 2011104S AbstractsScore (VCSS) and PTS scoring put forth by Villalta et al
(PTSV), commonly used scoring systems, were used to
appraise PTS at 3, 6, 12, 18 and 24 months following
diagnosis of DVT. Cumulative incidence (CI) served as
the primary outcome measure.
Results:Asmeasured by VCSS, the GCS (study) group
had a cumulative incidence of PTS that was twice that of the
control group. When PTSV was used as the instrument of
measurement, a significant difference in cumulative inci-
dence of PTS in the GCS and control groups was not
found. The break up of incidence at various time intervals is
depicted in table 1.
Conclusions: Use of knee length graduated compres-
sive stockings does not appear to prevent development of
post thrombotic syndrome. When PTS is assessed by the
VCSS instrument the use of stockings seem to contribute to
the incidence of the syndrome.
Table I.
VCSS (Incidence of PTS) PTSV (Incidence of PTS)
Month GCS Group Control Group GCS Group Control Group
3 58% 36% 50% 72%
6 56% 17% 63% 60%
12 59% 15% 59% 46%
18 73% 33% 59% 52%
24 68% 8% 42% 54%
Author Disclosures: A. Jayaraj: Nothing to disclose; M.
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Video Presentation
Resection of Vena Cava for Invasion by Renal Cell
Carcinoma
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Background: Up to 10% of patients with renal cell
carcinoma will have extension into the inferior vena cava. In
those cases, a vascular surgeon is usually asked to assist the
urologist in resection of the vena cava and removal of the
intra caval thrombus.
Technical Description: This video will outline the
operative approach for isolation of the suprahepatic cava
including the hepatic veins, the infrahepatic and infrarenal
vena cava, and the steps involved with removal of the
thrombus bymilking it back through the cava and resection
of the vena cava with non stenotic reconstruction. We have
performed 69 reconstructions with no perioperative
deaths; 80% of these patients required suprahepatic control
and 10% required median stenotomy for extension of the
thrombus into the atrium. The operative technique will be bllustrated and should be valuable for all surgeons who
articipate in this operation.
uthor Disclosures: B. B. Chang: Nothing to disclose;
. Darling: Nothing to disclose; P. B. Kreienberg: Noth-
ng to disclose; M. Mehta: Nothing to disclose; K. J.
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Objectives: Review evidence for anticoagulation treat-
ent of calf deep venous thrombosis (CDVT).
Methods: Medline, Cochrane Library, meeting ab-
tracts, and expert opinion were reviewed. Criteria for
tudies selected were: (1) Adults with CDVT by ultrasound
r venogram, (2) comparisons of patients treated with
nticoagulation (vitamin K antagonist or heparin) for 30
ays to controls (not anticoagulated), (3)  one month
ollow-up. Primary outcome was pulmonary embolus (PE).
econdary outcomes were clot propagation, post-throm-
otic syndrome, mortality, and bleeding. Two independent
eviewers extracted data from qualifying articles. Quality
ssessment was performed using standardized scales. Meta-
nalyses were performed by generating pooled odds ratios
ith subgroup and sensitivity analyses.
Results: We reviewed 2,328 studies, including 148 full
ext articles. Eight studies met selection criteria (2 RCTs
nd 6 cohort) providing 126 anticoagulated patients and
78 controls. Most studies were of poor methodological
uality and did not report all outcomes. Rates of PE (OR
.12, 95% CI 0.02-0.77, p0.03) and clot propagation
OR 0.29, 95% CI 0.14-0.62, p0.04, Figure 1) were
ignificantly lower in patients treated with anticoagulation.
ue to heterogeneity, results for bleeding complications
nd mortality could not be pooled, but favored controls or
nticoagulation respectively. No data on post-thrombotic
yndrome were available.
Conclusions: Anticoagulation for CDVT may de-
rease clinically important outcomes such as PE and clot
ropagation. Treatment-related complications have been
oorly documented and studies are of poormethodological
uality. More rigorous studies would improve evidenced
ased treatment for calf vein DVT.
